MedTrace Logo

Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women

NCT03201861 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 762

Last updated 2025-05-16

No results posted yet for this study

Summary

The investigators hypotheses that paclitaxel combined with cisplatin in a weekly-based regimen as adjuvant chemotherapy is more effective for high risk, HER2 negative breast cancer .

Conditions

  • Tubular Breast Cancer
  • Mucinous Breast Cancer
  • Invasive Duct Carcinoma of Breast

Interventions

DRUG

Paclitaxel, Cisplatin

weekly paclitaxel and cisplatin

DRUG

EC to docetaxel or paclitaxel

Standard adjuvant chemotherapy recommended by guideline

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Jinsong Lu, M.D. · Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-27
Primary Completion
2027-08-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03201861 on ClinicalTrials.gov